Minerva Neurosciences Inc (NERV) : Vivo Capital added new position in Minerva Neurosciences Inc during the most recent quarter end. The investment management firm now holds 200,000 shares of Minerva Neurosciences Inc which is valued at $2,330,000 , the company said in a statement filed on Aug 15, 2016 with the SEC.Minerva Neurosciences Inc makes up approximately 0.56% of Vivo Capital’s portfolio.
Other Hedge Funds, Including , Schwab Charles Investment Management Inc added NERV to its portfolio by purchasing 25,000 company shares during the most recent quarter which is valued at $291,250.Geode Capital Management boosted its stake in NERV in the latest quarter, The investment management firm added 64,392 additional shares and now holds a total of 99,728 shares of Minerva Neurosciences Inc which is valued at $1,161,831. Visium Asset Management Lp added NERV to its portfolio by purchasing 19,856 company shares during the most recent quarter which is valued at $231,322. Minerva Neurosciences Inc makes up approx 0.02% of Visium Asset Management Lp’s portfolio. Marshall Wace Llp added NERV to its portfolio by purchasing 261,505 company shares during the most recent quarter which is valued at $3,046,533. Minerva Neurosciences Inc makes up approx 0.02% of Marshall Wace Llp’s portfolio. California State Teachers Retirement System added NERV to its portfolio by purchasing 33,537 company shares during the most recent quarter which is valued at $369,578.
Minerva Neurosciences Inc opened for trading at $12.17 and hit $12.39 on the upside on Thursday, eventually ending the session at $12.35, with a gain of 1.06% or 0.13 points. The heightened volatility saw the trading volume jump to 1,48,709 shares. Company has a market cap of $430 M.
On the company’s financial health, Minerva Neurosciences Inc reported $-0.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.30.During the same quarter in the previous year, the company posted $-0.27 EPS.
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. Its lead product candidate is MIN-101 a compound for the potential treatment of patients with schizophrenia. Its product pipeline also includes MIN-117 MIN-202 and MIN-301. MIN-101 is a compound it is developing for the treatment of patients with schizophrenia. MIN-117 is a compound for the potential treatment of patients suffering from major depressive disorder (MDD). MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen for the treatment of insomnia. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein for the treatment of Parkinson’s disease.